Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections
- Written by PR Newswire Asia - Daily Bulletin Au RSS
BANGALORE, India; SARATOGA, Calif. and ADELAIDE, Australia, Nov. 8, 2021 /PRNewswire/ -- Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), supported by Combating Antibiotic-Resistant Bacteria...